Tuesday, July 22, 2025 7/22/2025

Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity

Award Number: R01CA168863
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2013
PERIOD OF PERFORMANCE END DATE: 12/31/2024

Group Awards By:

View Award Description

Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity - PROJECT SUMMARY/ABSTRACT A Phase 1b clinical trial of dual myeloid blockade in metastatic pancreatic adenocarcinoma (PDAC) is planned. Patients will be treated with standard chemotherapy (FOLFIRINOX) and 2 orally available, small molecule allosteric chemokine receptor inhibitors to CCR2 (CXC872) and CXCR1/2 (SX682). The primary endpoint of the trial is safety and tolerability, and the secondary endpoint is clinical effectiveness as measured by progression free survival at 24 weeks. Baseline and on treatment tumor biopsies will be subjected to genomic analysis as well as sophisticated immune monitoring using mass cytometry. Genetic and immunologic biomarkers of treatment resistance and response will be explored. Preclinical studies will also be performed throughout the study to inform and perfect subsequent clinical translation of the most effective ways to immunologically reprogram the immunosuppressive tumor microenvironment that is characteristic of PDAC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$41,132 )
2025	2023	UNIVERSITY OF ROCHESTER	910 GENESEE ST	ROCHESTER	NY	14611	MONROE	USA	Cancer Treatment Research	000	10	4/24/2025	NON-COMPETING CONTINUATION	-$41,132
														Subtotal = -$41,132

Issue Date FY: 2023 ( Subtotal = $334,305 )
2023	2023	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	000	10	1/30/2023	NON-COMPETING CONTINUATION	$334,305
														Subtotal = $334,305

Issue Date FY: 2022 ( Subtotal = $338,099 )
2022	2022	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	001	9	3/15/2022	NON-COMPETING CONTINUATION	$255,940
2022	2022	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	002	9	6/23/2022	NON-COMPETING CONTINUATION	$82,159
2022	2021	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	000	8	2/18/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $338,099

Issue Date FY: 2021 ( Subtotal = $522,237 )
2021	2021	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	001	8	1/26/2021	NON-COMPETING CONTINUATION	$26,113
2021	2021	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	000	8	12/24/2020	NON-COMPETING CONTINUATION	$496,124
														Subtotal = $522,237

Issue Date FY: 2020 ( Subtotal = $469,165 )
2020	2020	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	002	7	8/27/2020	SUPPLEMENT FOR EXPANSION	$118,067
2020	2020	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	000	7	12/26/2019	NON-COMPETING CONTINUATION	$315,987
2020	2020	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	001	7	1/15/2020	NON-COMPETING CONTINUATION	$35,111
														Subtotal = $469,165

Issue Date FY: 2019 ( Subtotal = $349,385 )
2019	2019	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	000	6	12/19/2018	COMPETING CONTINUATION	$349,385
2019	2019	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	002	6	1/31/2019	COMPETING CONTINUATION	$10,649
2019	2017	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	001	5	1/31/2019	NON-COMPETING CONTINUATION	-$10,649
														Subtotal = $349,385

Issue Date FY: 2017 ( Subtotal = $319,377 )
2017	2017	UNIVERSITY OF ROCHESTER	601 ELMWOOD AVE	ROCHESTER	NY	14642	MONROE	USA	Cancer Treatment Research	000	5	5/1/2017	NON-COMPETING CONTINUATION	$287,440
2017	2017	UNIVERSITY OF ROCHESTER	500 JOSEPH C WILSON BLVD	ROCHESTER	NY	14627	MONROE	USA	Cancer Treatment Research	001	5	6/7/2017	NON-COMPETING CONTINUATION	$31,937
														Subtotal = $319,377

Issue Date FY: 2016 ( Subtotal = $318,513 )
2016	2016	UNIVERSITY OF ROCHESTER	1325 MOUNT HOPE AVE, SUITE 260	ROCHESTER	NY	14642	MONROE	USA	Cancer Treatment Research	000	4	5/15/2016	NON-COMPETING CONTINUATION	$318,513
														Subtotal = $318,513

Issue Date FY: 2015 ( Subtotal = $318,513 )
2015	2015	UNIVERSITY OF ROCHESTER	1325 MOUNT HOPE AVE, SUITE 260	ROCHESTER	NY	14642	MONROE	USA	Cancer Treatment Research	001	3	9/16/2015	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$318,513
2015	2014	WASHINGTON UNIVERSITY	CAMPUS BOX 1034	SAINT LOUIS	MO	63112	SAINT LOUIS CITY	USA	Cancer Treatment Research	000	2	9/16/2015	NON-COMPETING CONTINUATION	$0
														Subtotal = $318,513

Issue Date FY: 2014 ( Subtotal = $305,938 )
2014	2014	WASHINGTON UNIVERSITY	CAMPUS BOX 1034	SAINT LOUIS	MO	63112	SAINT LOUIS CITY	USA	Cancer Treatment Research	000	2	5/6/2014	NON-COMPETING CONTINUATION	$305,938
														Subtotal = $305,938

Issue Date FY: 2013 ( Subtotal = $315,400 )
2013	2013	WASHINGTON UNIVERSITY	CAMPUS BOX 1034	SAINT LOUIS	MO	63112	SAINT LOUIS CITY	USA	Cancer Treatment Research	000	1	6/14/2013	NEW	$315,400
														Subtotal = $315,400

Grand Total All Awards = $3,549,800

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity

Award Number: R01CA168863

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2013

PERIOD OF PERFORMANCE END DATE: 12/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer